PE-Labeled Human CD19 (20-291) Protein, His Tag (Site-specific conjugation)

分子別名（Synonym）

CD19,B4,CVID3,MGC12802

表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）

PE-Labeled Human CD19 (20-291), His Tag (CD9-HP2H3) is produced via site-specific conjugation of PE to Human CD19 (20-291), His Tag under optimal conditions with a proprietary technology. Human CD19 (20-291), His Tag is expressed from human 293 cells (HEK293). It contains AA Pro 20 - Lys 291 (Accession # P15391-1).

Predicted N-terminus: Pro 20

蛋白結(jié)構(gòu)（Molecular Characterization）

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 33.7 kDa.

偶聯(lián)（Conjugate）

PE

Excitation Wavelength: 488 nm / 561 nm

Emission Wavelength: 575 nm

應(yīng)用說明（Application）

Evaluation of anti-CD19 CAR expression by flow cytometry. Please note that this product is NOT compatible to streptavidin detection system.

制劑（Formulation）

Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重構(gòu)方法（Reconstitution）

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存儲（Storage）

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:

-20°C to -70°C for 12 months in lyophilized state;

-70°C for 3 months under sterile conditions after reconstitution.

背景（Background）

B淋巴細(xì)胞抗原CD19也稱為CD19（分化簇19），是一種單程I型膜蛋白，含有兩個Ig樣C2型（免疫球蛋白樣）結(jié)構(gòu)域。CD19在濾泡樹突細(xì)胞和B細(xì)胞上表達(dá)。事實上，它存在于B細(xì)胞上，從發(fā)育過程中最早可識別的B譜系細(xì)胞到B細(xì)胞母細(xì)胞，但在成熟為漿細(xì)胞時丟失。它主要作為與CD21和CD81結(jié)合的B細(xì)胞共受體。激活后，CD19的細(xì)胞質(zhì)尾部被磷酸化，導(dǎo)致Src家族激酶結(jié)合并募集PI-3激酶。與T細(xì)胞一樣，幾個表面分子形成抗原受體，并在B淋巴細(xì)胞上形成復(fù)合物。（幾乎）B細(xì)胞特異性CD19磷酸糖蛋白就是這些分子之一。其他是CD21和CD81。這些表面免疫球蛋白（sIg）相關(guān)分子促進(jìn)信號轉(zhuǎn)導(dǎo)。在活的B細(xì)胞上，模擬外源性抗原的抗免疫球蛋白抗體使CD19與sIg結(jié)合并內(nèi)化。相反的過程尚未得到證實，這表明這種受體復(fù)合物的形成是由抗原誘導(dǎo)的。這種分子關(guān)聯(lián)已被化學(xué)研究證實。CD19突變與以抗體產(chǎn)生減少為特征的嚴(yán)重免疫缺陷綜合征有關(guān)。CD19已被證明與CD81、CD82、補體受體2和VAV2相互作用。